NCT03318939 2024-04-03
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
Spectrum Pharmaceuticals, Inc
Istituto Clinico Humanitas
Hanmi Pharmaceutical Company Limited
Millennium Pharmaceuticals, Inc.